text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2024년 06월 30일\n)\n(단위 : 백만원, 천주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n에이치엘비생활건강㈜\n비상장\n2018.08.20\n경영참여\n\xa012,193\r\n\xa0 \xa0 \xa0 \xa01,333\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0\xa01,333\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0\xa01,774\r\n-1,074\n㈜프레시코 보통주\n비상장\n2020.01.20\n경영참여\n\xa0\xa038,995\r\n\xa0 \xa0 \xa0 \xa0 \xa0\xa088\r\n\xa0 \xa0 \xa0 \xa082\r\n9,048\r\n\xa0 \xa0 \xa0 \xa025\r\n\xa0 \xa0\xa02,612\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0113\r\n\xa0 \xa0\xa02,694\r\n\xa0\xa011,660\r\n\xa0\xa025,228\r\n-7,097\n㈜프레시코 우선주\n비상장\n2022.09.06\n경영참여\n\xa0 \xa0\xa06,008\r\n\xa0 \xa0 \xa0 \xa0 \xa0\xa012\r\n\xa0 \xa0 \xa0 \xa011\r\n6,008\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0\xa012\r\n\xa0 \xa0 \xa0 \xa011\r\n\xa0 \xa0\xa06,008\r\n\xa0\xa025,228\r\n-7,097\n㈜모던파파스\n비상장\n2023.07.01\n경영참여\n\xa0 \xa0 \xa0 \xa0 \xa05\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0 \xa05\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0 \xa0 \xa05\r\n\xa0 \xa0 \xa0\xa0120\r\n\xa0 \xa0 \xa0 \xa014\r\n㈜퍼플리쉬\n비상장\n2023.07.01\n경영참여\n\xa0 \xa0 \xa0\xa0301\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0\xa0301\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0\xa0301\r\n\xa0 \xa0 \xa0\xa0218\r\n-104\n㈜더롬다이어트\n비상장\n2023.07.01\n경영참여\n\xa0 \xa0 \xa0\xa0150\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0\xa0150\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0\xa0100\r\n\xa0 \xa0 \xa0\xa0150\r\n\xa0 \xa0 \xa0\xa0299\r\n-136\n㈜데님오브벌츄코리아\n비상장\n2018.09.12\n경영참여\n\xa0 \xa0\xa07,050\r\n\xa0 \xa0 \xa0 \xa0 \xa0232\r\n\xa0 \xa0 \xa0 \xa046\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0232\r\n\xa0 \xa0 \xa0 \xa046\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n에이치엘비사이언스㈜\n상장\n2018.10.15\n경영참여\n\xa0\xa010,064\r\n\xa0 \xa0 \xa0 \xa05,907\r\n\xa0 \xa0 \xa0 \xa036\r\n4,370\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0\xa05,907\r\n\xa0 \xa0 \xa0 \xa036\r\n\xa0 \xa0\xa04,370\r\n\xa0 \xa0\xa03,950\r\n-2,798\n에이치밸류에셋㈜ 보통주(*1)\n비상장\n2024.02.22\n단순투자\n\xa0 \xa0 \xa0\xa0600\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0\xa0120\r\n\xa0 \xa0 \xa0\xa0600\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0120\r\n\xa0 \xa0 \xa0 \xa0 \xa02\r\n\xa0 \xa0 \xa0\xa0600\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n에이치밸류에셋㈜ 우선주(*1)\n비상장\n2024.02.23\n단순투자\n\xa0 \xa0\xa01,400\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0\xa0280\r\n\xa0 \xa0\xa01,400\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0280\r\n\xa0 \xa0 \xa0 \xa0 \xa04\r\n\xa0 \xa0\xa01,400\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n㈜룩스앤메이코스메틱\n비상장\n2019.03.28\n단순투자\n\xa0 \xa0 \xa0 \xa019\r\n\xa0 \xa0 \xa0 \xa0 \xa0\xa038\r\n\xa0 \xa0 \xa0 \xa017\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0\xa038\r\n\xa0 \xa0 \xa0 \xa017\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n강원일보\n비상장\n1981.04.30\n단순투자\n\xa0 \xa0 \xa0 \xa021\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa04\r\n\xa0 \xa0 \xa0 \xa0 \xa01\r\n\xa0 \xa0 \xa0 \xa021\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa04\r\n\xa0 \xa0 \xa0 \xa0 \xa01\r\n\xa0 \xa0 \xa0 \xa021\r\n\xa0\xa017,675\r\n\xa0 \xa0 \xa0\xa0204\r\n주식회사 인천유나이티드\n비상장\n2009.02.09\n단순투자\n\xa0 \xa0 \xa0 \xa0 \xa02\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa03\r\n\xa0 \xa0 \xa0 \xa0 \xa00\r\n\xa0 \xa0 \xa0 \xa0 \xa02\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa03\r\n\xa0 \xa0 \xa0 \xa0 \xa00\r\n\xa0 \xa0 \xa0 \xa0 \xa02\r\n\xa0 \xa0\xa03,863\r\n\xa0 \xa0\xa02,086\r\nNanogen Pharmaceutical Biotechnology JSC\n비상장\n2018.12.13\n단순투자\n\xa0\xa026,133\r\n\xa0 \xa0 \xa0 \xa07,475\r\n\xa0 \xa0 \xa0 \xa0 \xa09\r\n\xa0 \xa0 \xa0\xa0490\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0\xa07,475\r\n\xa0 \xa0 \xa0 \xa0 \xa09\r\n\xa0 \xa0 \xa0\xa0490\r\n\xa0122,605\r\n\xa0 \xa0\xa02,532\r\nImmunomic Therapeutics, Inc.\n비상장\n2020.04.23\n단순투자\n\xa0 \xa0\xa06,160\r\n\xa0 \xa0 \xa0 \xa01,000\r\n\xa0 \xa0 \xa0 \xa0 \xa04\r\n\xa0 \xa0\xa03,958\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0\xa01,000\r\n\xa0 \xa0 \xa0 \xa0 \xa04\r\n\xa0 \xa0\xa03,958\r\n\xa0\xa022,512\r\n-104\nHLB테라퓨틱스\n상장\n2021.11.16\n단순투자\n\xa0\xa015,000\r\n\xa0 \xa0 \xa0 \xa03,241\r\n\xa0 \xa0 \xa0 \xa0 \xa04\r\n\xa0\xa014,212\r\n-1,047\n-11,245\n\xa0\xa012,435\r\n\xa0 \xa0 \xa0\xa02,194\r\n\xa0 \xa0 \xa0 \xa0 \xa03\r\n\xa0\xa015,402\r\n\xa0215,682\r\n\xa0 \xa0 \xa01,038\r\n합 계\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa038,565\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n-6,633\n\xa0 \xa0 \xa012,435\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0-\r\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0-\r\n\xa0 \xa0 \xa044,367\r\n\xa0 \xa0\xa0439,154\r\n-12,536\n※ 상기 자료는 당사의 별도 재무제표상 투자법인 금액이며, 지분율 산정시 총발행주식수에서 자기주식수를 제외하였습니다.※ 최근사업연도 재무현황은 2023년말 별도재무제표 기준이며, 최종 금액은 시점 및 회계기준에 따라 차이가 발생할 수 있습니다.※ 최초취득금액은 원시취득원가에 추가취득과 처분이 반영된 금액입니다.※ (*1) 당반기중 신규출자를 통해 유의적인 영향력을 획득함에 따라 관계기업에 편입되었습니다.\n']"
